Offer - Urjas Oil for just ₹ 1 X
Clomistar 50 Tablet is a commercial drug that is prescribed in the form of Tablet. It is typically used for the treatment of Obsessive Compulsive Disorder.
The correct dosage of Clomistar 50 Tablet depends on the patient's age, gender, and medical history. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. This information has been provided in detail in the dosage section.
Apart from the aforementioned side effects, Clomistar 50 Tablet can also lead to other problems, which have been listed below. Such side effects of Clomistar 50 Tablet normally do not last long and go away once the treatment is completed. Please speak with your doctor if these side effects worsen or persist for a longer duration.
In addition, Clomistar 50 Tablet's effect is Moderate during pregnancy and Severe for lactating mothers. It is important to know if Clomistar 50 Tablet has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Clomistar 50 Tablet related warnings section.
Clomistar 50 Tablet can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Clomistar 50 Tablet in conditions like Heart Disease, Coronary Artery Disease (CAD), Suicidal Tendency. The section on Clomistar 50 Tablet contraindications lists all such conditions.
Besides this, Clomistar 50 Tablet may also have severe interaction with some medicines. Refer to the list below for further details.
You should also be aware that Clomistar 50 Tablet is not safe while driving, and is not addiction.
Clomistar 50 Tablet is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
Is the use of Clomistar 50 Tablet safe for pregnant women?
Clomistar may cause moderate side effects during pregnancy. If you feel its harmful effects, then stop taking this drug immediately, and do not take Clomistar again without your doctor's advice.
Is the use of Clomistar 50 Tablet safe during breastfeeding?
Women who are breastfeeding may experience severe harmful effects after taking Clomistar. It should only be taken after medical advice.
What is the effect of Clomistar 50 Tablet on the Kidneys?
Clomistar is completely safe for kidneys.
What is the effect of Clomistar 50 Tablet on the Liver?
Clomistar may have mild side effects on the liver. Most people will never see any effect on the liver.
What is the effect of Clomistar 50 Tablet on the Heart?
Clomistar may have mild side effects on the heart. Most people will never see any effect on the heart.
If you are suffering from any of the following diseases, you should not take Clomistar 50 Tablet unless your doctor advises you to do so -
Is this Clomistar 50 Tablet habit forming or addictive?
No, you will not get addicted to Clomistar 50 Tablet.
Is it safe to drive or operate heavy machinery when consuming?
After taking Clomistar 50 Tablet you may feel sleepy. So it is not advised to perform these activities.
Is it safe?
Yes, but take Clomistar 50 Tablet only as per medical advice.
Is it able to treat mental disorders?
Yes, Clomistar 50 Tablet is useful in treating mental disorders.
Interaction between Food and Clomistar 50 Tablet
Taking Clomistar 50 Tablet with food is safe.
Interaction between Alcohol and Clomistar 50 Tablet
Taking alcohol with Clomistar 50 Tablet can be dangerous.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Anafranil® (clomipramine hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 454, 456, 458, 464